Verubecestat
Clinical data | |
---|---|
Other names | MK-8931 |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
JSmol) | |
| |
|
Verubecestat (MK-8931) was an experimental drug for the treatment of Alzheimer's disease.[1] It is an inhibitor of beta-secretase 1 (BACE1),[2][3][4] which, after initial promise proved disappointing.
In April 2012 phase I clinical results were announced.[5] Phase 1b results have also been reported.[3][2]
As of December 2016[update] it was in two phase 2/3 clinical trials that have progressed to phase 3.
References
- ^ a b Makin S (2 November 2016). "New Alzheimer's drug clears milestone in human clinical trial". Scientific American.
- ^ S2CID 54387517.
- ^ PMID 24556009.
- S2CID 4579605.
- ^ "Merck presents results of a phase I clinical trial evaluating investigational BACE inhibitor MK-8931 at American Academy of Neurology". Merck Sharp & Dohme Corp. April 2012. Archived from the original on 2012-07-28. Retrieved 2012-07-16.
- ^ Clinical trial number NCT01953601 for "Efficacy and safety trial of verubecestat (MK-8931) in participants with prodromal Alzheimer's disease (MK-8931-019) (APECS)" at ClinicalTrials.gov
- ^ a b Clinical trial number NCT01739348 for "An efficacy and safety trial of verubecestat (MK-8931) in mild to moderate Alzheimer's disease (P07738) (EPOCH)" at ClinicalTrials.gov
- ^ "Merck announces EPOCH study of verubecestat for the treatment of people with mild to moderate Alzheimer's disease to stop for lack of efficacy" (Press release). Merck Sharp & Dohme Corp. 14 February 2017.
- ^ Barber J (13 February 2018). "Merck & Co. terminates Phase III study of verubecestat in prodromal Alzheimer's disease". FirstWord Pharma.
- ^ Clinical trial number NCT01953601 for "Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)" at ClinicalTrials.gov
- PMID 29719179.